BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36412315)

  • 21. Acute promyelocytic leukemia current treatment algorithms.
    Yilmaz M; Kantarjian H; Ravandi F
    Blood Cancer J; 2021 Jun; 11(6):123. PubMed ID: 34193815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
    Zhu G
    Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What is the role of arsenic in newly diagnosed APL?
    Tallman MS
    Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapies for newly diagnosed acute promyelocytic leukemia].
    Yokoyama Y
    Rinsho Ketsueki; 2020; 61(9):1166-1173. PubMed ID: 33162512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
    Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
    Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
    Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H
    Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia.
    Hasan SK; Lo-Coco F
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10 Suppl 3():S139-43. PubMed ID: 21115433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment Outcomes Of Patients With Newly Diagnosed Acute Promyelocytic Leukemia; Experience From A Developing Country.
    Javed H; Chudary QU; Iftikhar R; Shahbaz N; Ali M; Hamayun S
    J Ayub Med Coll Abbottabad; 2022; 34(4):791-796. PubMed ID: 36566401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case Report: Co-existence of a novel
    Liu X; Li W; Xiao J; Zhong H; Yang K
    Front Oncol; 2023; 13():1165819. PubMed ID: 37152017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Testa U; Lo-Coco F
    Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
    Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute promyelocytic leukemia with the translocation t(15;17)(q22;q21) associated with t(1;2)(q42~43;q11.2~12): a case report.
    Wafa A; Moassass F; Liehr T; Al-Ablog A; Al-Achkar W
    J Med Case Rep; 2016 Jul; 10():203. PubMed ID: 27459859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
    Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
    Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chromosomal abnormality of acute promyelocytic leukemia other than
    Imataki O; Uemura M
    BMC Clin Pathol; 2016; 16():16. PubMed ID: 27708545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
    Lo-Coco F; Hasan SK
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autophagic degradation of an oncoprotein.
    Bøe SO; Simonsen A
    Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
    Tomita A; Kiyoi H; Naoe T
    Int J Hematol; 2013 Jun; 97(6):717-25. PubMed ID: 23670176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel clonal t(1;4)(p36.1;q31) translocation in acute promyelocytic leukaemia.
    Zhang X; Pan J
    J Clin Pathol; 2015 May; 68(5):391-3. PubMed ID: 25759405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of concurrent STAT3::RARA and RARA::STAT5b fusions in a variant APL case.
    Tao T; Cen J; Xu C; Chen Y; Cao Y; Gong Y; Zhu M; Chen S; Zhang Q; Yao L
    Mol Carcinog; 2024 Apr; 63(4):558-562. PubMed ID: 38153216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
    Guo W; Wang H; Zhao W
    Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):327-31. PubMed ID: 11798779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.